Geoffrey R. Oxnard, MD

Articles by Geoffrey R. Oxnard, MD

42 Tissue and Liquid Biopsy–Based Comprehensive Genomic Profiling Reveal Mechanisms of Therapy Resistance and Rare Targetable Alterations in Breast Cancer

ByEthan Sokol,Smruthy Sivakumar,Dexter X. Jin,Hanna Tukachinsky,Karthikeyan Murugesan,Dean Pavlick,Jeffrey S. Ross, MD,Garrett M. Frampton,Geoffrey R. Oxnard, MD,Priti S. Hegde

April 18th 2022

Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC

ByGeoffrey R. Oxnard, MD,Vincent A. Miller, MD

April 30th 2010

Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of patients with non–small-cell lung cancer (NSCLC).

Latest Updated Articles

Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC
April 30th 2010

Trending on CancerNetwork

FDA Approves Atezolizumab in MIBC Post-Cystectomy with ctDNA MRD

Yoga Could Alter Cancer-Related Fatigue Levels Across Solid Tumors

109 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Final Results from the Multi-national, Prospective, Observational Study ELEANOR